The effect of statins on carotid plaque morphology: A LDL-associated action or one more pleiotropic effect of statins?

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 8-20

  Makris, Gregory C ^a,b,d   Lavida, Anthi ^c   Nicolaides, Andrew N ^a   Geroulakos, George ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b EALING HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

Author keywords

Carotid plaque; Morphology; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CLOPIDOGREL; COLESTIPOL; FLUINDOSTATIN; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; HUMAN; HYPERCHOLESTEROLEMIA; IMAGING SYSTEM; INFLAMMATION; LOW DRUG DOSE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULTRASOUND;

CARDIOLOGY; CAROTID ARTERY DISEASES; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPOPROTEINS, LDL; MAGNETIC RESONANCE IMAGING; MALE; ULTRASONOGRAPHY;

EID: 77956525807     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.04.032     Document Type: Review

References (85)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
2. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
3. Amarenco P., Labreuche J., Lavallee P., et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35:2902-2909.
4. Amarenco P., Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009, 8:453-463.
5. Amarenco P., Bogousslavsky J., Callahan A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
6. Stalenhoef A.F. The benefit of statins in non-cardiac vascular surgery patients. J Vasc Surg 2009, 49:260-265.
7. Paraskevas K.I., Liapis C.D., Hamilton G., Mikhailidis D.P. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur J Vasc Endovasc Surg 2006, 32:286-293.
8. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
9. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006, 295:1556-1565.
10. Slim K., Nini E., Forestier D., et al. Methodological index for nonrandomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003, 73:712-716.
11. Moher D., Pham B., Jones A., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998, 352:609-613.
12. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001, 21:1623-1629.
13. Corti R., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002, 106:2884-2887.
14. Schminke U., Hilker L., Motsch L., Griewing B., Kessler C. Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy. J Neuroimaging 2002, 12:245-251.
15. Adams G.J., Greene J., Vick G.W., et al. Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magn Reson Imaging 2004, 22:1249-1258.
16. Ainsworth C.D., Blake C.C., Tamayo A., Beletsky V., Fenster A., Spence J.D. 3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies. Stroke 2005, 36:1904-1909.
17. Corti R., Fuster V., Fayad Z.A., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005, 46:106-112.
18. Watanabe K., Sugiyama S., Kugiyama K., et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in non-hypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005, 46:2022-2030.
19. Saam T., Yuan C., Chu B., et al. Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis 2007, 194:e34-e42.
20. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48:1825-1831.
21. Phan B.A., Chu B., Polissar N., Hatsukami T.S., Yuan C., Zhao X.Q. Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging. Int J Cardiovasc Imaging 2007, 23:337-342.
22. Kadoglou N.P., Gerasimidis T., Moumtzouoglou A., et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 2008, 35:661-668.
23. Yamagami H., Sakaguchi M., Furukado S., et al. Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound Med Biol 2008, 34:1353-1359.
24. Underhill H.R., Yuan C., Zhao X.Q., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008, 155. 584.e1-584.e8.
25. Nakamura T., Obata J.E., Kitta Y., et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008, 51:365-371.
26. Boussel L., Arora S., Rapp J., et al. Atherosclerotic plaque progression in carotid arteries: monitoring with high-spatial-resolution MR imaging-multicenter trial. Radiology 2009, 252:789-796.
27. Kadoglou N.P., Sailer N., Moumtzouoglou A., Kapelouzou A., Gerasimidis T., Liapis C.D. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg 2009, October 16 [Epub ahead of print].
28. Yamada K., Yoshimura S., Kawasaki M., et al. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound. Cerebrovasc Dis 2009, 28:417-424.
29. Katakami N., Sakamoto K., Kaneto H., et al. Lipid-lowering with atorvastatin improves tissue characteristics of carotid plaque. Atherosclerosis 2005, 183:369-371.
30. Stivali G., Cerroni F., Bianco P., Fiaschetti P., Cianci R. Images in cardiovascular medicine. Carotid plaque reduction after medical treatment. Circulation 2005, 112:e276-e277.
31. Zhao X.Q., Phan B.A., Chu B., et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am Heart J 2007, 154:239-246.
32. Krasinski A., Chiu B., Spence J.D., Fenster A., Parraga G. Three-dimensional ultrasound quantification of intensive statin treatment of carotid atherosclerosis. Ultrasound Med Biol 2009, 35:1763-1772.
33. Celletti F., Waugh J., Amabile P., et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001, 7:425-429.
34. Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998, 98:2108-2116.
35. Migrino R. Carotid plaque regression with statin treatment assessed by high field magnetic resonance imaging 2006 October, Medical College of Wisconsin. http://www.clinicaltrials.gov/.
36. Morrisett J.D. Effect of short term atorvastatin treatment, 80mg/day on early regression of carotid artery atherosclerotic lesions (DCAT) 2008 January, Baylor College of Medicine. http://www.clinicaltrials.gov/.
37. Kai H. Detection of plaque inflammation by positron emission tomography (PET)-effects of simvastatin on plaque inflammation 2005 June, Kurume University. http://www.clinicaltrials.gov/.
38. Medical Monitor Merck Merck carotid atherosclerosis trial 2008 December, Merck. http://www.clinicaltrials.gov/.
39. Choi K.M. Effect of atorvastatin on vascular inflammation in type 2 diabetes 2009 July, Korea University. http://www.clinicaltrials.gov/.
40. GSK Clinical Trials Effects of atorvastatin on macrophage activity and plaque inflammation using magnetic resonance imaging 2006 August, GlaxoSmithKline. http://www.clinicaltrials.gov/.
41. Zhao X.-Q. Using magnetic resonance imaging to evaluate carotid artery plaque composition in people receiving cholesterol-lowering medications (The CPC study) 2008 July, National Heart, Lung, and Blood Institute (NHLBI). http://www.clinicaltrials.gov/.
42. Ahlström H. Effects of crestor on inflammation of atherosclerotic plaques 2008 May, AstraZeneca. http://www.clinicaltrials.gov/.
43. Matsumoto M. Carotid intima-media thickness in Japan statin treatment against recurrent stroke (J-STARS Echo) 2006 August, Translational Research Informatics Center, Kobe, Hyogo, Japan. http://www.clinicaltrials.gov/.
44. Anti-inflammatory effect of atorvastatin in atherosclerotic plaques assessed by FDG-PET imaging 2009 June, National Defence Medical College, Japan. http://www.clinicaltrials.gov/.
45. Lerman A. The acute effect of statins on inflammatory markers of athersclerotic tissue 2007 December, Mayo Clinic. http://www.clinicaltrials.gov/.
46. Petri M.A. Lupus atherosclerosis prevention study 2005 July, Johns Hopkins University. http://www.clinicaltrials.gov/.
47. Liapis C. Diagnosis and therapy of vulnerable atherosclerotic plaque 2008 March, Aristotle University of Thessaloniki. http://www.clinicaltrials.gov/.
48. Bondy G. Effectiveness of rosuvastatin at preventing the progression of atherosclerosis in HIV positive patients 2008 April, University of British Columbia. http://www.clinicaltrials.gov/.
49. Lima J.A.C. High-density lipoprotein (HDL) cholesterol increased plaque stabilization in the elderly 2005 August, National Institute on Aging (NIA). http://www.clinicaltrials.gov/.
50. Bristol-Myers Squibb Efficacy study of p38 kinase inhibitor to treat patients with atherosclerosis 2007 December, Bristol-Myers Squibb. http://www.clinicaltrials.gov/.
51. Li E.K.M. Effects of HMG-coA reductase inhibitor on rheumatoid arthritis 2007 November, Chinese University of Hong Kong. http://www.clinicaltrials.gov/.
52. Franz W.M. Niacin as secondary prevention of coronary artery disease (NASPOCAD) 2007 February, Ludwig-Maximilians-University of Munich. http://www.clinicaltrials.gov/.
53. Reilly M.P. Carotid atherosclerosis regression at magnetic resonance assessment 2006 March, University of Pennsylvania. http://www.clinicaltrials.gov/.
54. Paraskevas K.I., Hamilton G., Mikhailidis D.P. Statins: an essential component in the management of carotid artery disease. J Vasc Surg 2007, 46:373-386.
55. Spence J.D. Measurement of intima-media thickness vs. carotid plaque: uses in patient care, genetic research and evaluation of new therapies. Int J Stroke 2006, 1:216-221.
56. Coll B., Feinstein S.B. Carotid intima-media thickness measurements: techniques and clinical relevance. Curr Atheroscler Rep 2008, 10:444-450.
57. Zhou Z., Rahme E., Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006, 151:273-281.
58. Nakamura K., Sasaki T., Cheng X.W., Iguchi A., Sato K., Kuzuya M. Statin preventsplaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009, 206:355-361.
59. Jackson C.L., Johnson J.L. Statin pleiotropism and atherosclerotic plaque rupture. Atherosclerosis 2009, 206:353-435.
60. Amarenco P., Labreuce J., Touboul P.J. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008, 196:489-496.
61. Labreuce J., Touboul P.J., Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis 2009, 203:331-345.
62. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
63. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel, III). JAMA 2001, 285:2486-2497.
64. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
65. Corti R., Osende J., Hutter R., et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 2007, 190:106-113.
66. Iso H., Rexrode K.M., Stampfer M.J., et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001, 285:304-312.
67. He K., Rimm E.B., Merchant A., et al. Fish consumption and risk of stroke in men. JAMA 2002, 288:3130-3136.
68. Mita T., Watada H., Ogihara T., et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007, 191:162-167.
69. Gao P., Chen Z.Q., Bao Y.H., Jiao L.Q., Ling F. Correlation between carotid intraplaque hemorrhage and clinical symptoms: systematic review of observational studies. Stroke 2007, 38:2382-2390.
70. Fisher M., Paganini-Hill A., Martin A., et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke 2005, 36:253-257.
71. Gao P., Chen Z.Q., Jiao L.Q., Ling F. The correlation of carotid plaque pathohistologic features and neurological symptoms: a meta-analysis of observational studies. Neurol India 2007, 55:122-129.
72. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
73. Johnsen S.H., Mathiesen E.B., Joakimsen O., et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromsø Study. Stroke 2007, 38:2873-2880.
74. Box F.M., van der Grond J., de Craen A.J., et al. Pravastatin decreases wall shear stress and blood velocity in the internal carotid artery without affecting flow volume: results from the PROSPER MRI study. Stroke 2007, 38:1374-1376.
75. Bang J., Dahl T., Bruinsma A., Kaspersen J.H., Nagelhus Hernes T.A., Myhre H.O. A new method for analysis of motion of carotid plaques from RF ultrasound images. Ultrasound Med Biol 2003, 29:967-976.
76. Augst A.D., Barratt D.C., Hughes A.D., Glor F.P., McG Thom S.A., Xu X.Y. Accuracy and reproducibility of CFD predicted wall shear stress using 3D ultrasound images. J Biomech Eng 2003, 125:218-222.
77. Liao J.K. Safety and efficacy of statins in Asians. Am J Cardiol 2007, 99:410-414.
78. Saam T., Cai J.M., Cai Y.Q., et al. Carotid plaque composition differs between ethno-racial groups. Arterioscler Thromb Vasc Biol 2005, 25:611-616.
79. Kajinami K., Akao H., Polisecki E., Schaefer E.J. Pharmacogenomics of statin responsiveness. Am J Cardiol 2005, 96(Suppl.):65K-70K.
80. Kips J.G., Segers P., Van Bortel L.M. Identifying the vulnerable plaque: a review of the invasive and non-invasive imaging modalities. Artery Res 2008, 2:21-34.
81. Chiu B., Egger M., Spence J.D., Parraga G., Fenster A. Quantification of carotid vessel wall and plaque thickness change using 3D ultrasound images. Med Phys 2008, 35:3691-3710.
82. Landry A., Spence J.D., Fenster A. Quantification of carotid plaque volume measurements using 3D ultrasound imaging. Ultrasound Med Biol 2005, 31:751-762.
83. Hatsukami T.S., Ross R., Polissar N.L., Yuan C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation 2000, 102:959-964.
84. Fuster V., Fayad Z.A., Moreno P.R., Poon M., Corti R., Badimon J.J. Atherothrombosis and high-risk plaque. Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005, 46:1209-1218.
85. Landini L., Santarelli M.F., Pingitore A., Positano V. New technological developments in the clinical imaging of atherosclerotic plaque. Curr Pharm Des 2003, 9:2403-2415.